Clinical trials: Metastatic Malignant Neoplasm to Brain
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Brain Metastases, Adult, Radiotherapy
Radiotherapy of Multiple Brain Metastases Using AGuIX®
This is a Prospective Randomized Open Blinded Endpoint phase II clinical trial. The study will be adaptive: an interim analysis is planned after enrolment of 20 patients in each arm of treatment (WBRT and AGuIX® + WBRT), to…
- Trial name
- NANORAD2 (NCT03818386)
- Testing
- AGuIX®, Whole Brain Radiation Therapy
- Where
- 14 sites in France
- Volunteers
- 106 people
- Sponsor
- University Hospital, Grenoble
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
This phase II trial tests how well cemiplimab works in treating patients with PD-L1 >= 50% non-small cell lung cancer (NSCLC) that has spread from where it first started (primary site) to the brain (metastases).
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT05840770
- Testing
- Biospecimen Collection, Cemiplimab, Computed Tomography
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors, Metastatic Cancer
CCI-779 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003712
- Testing
- temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Brain and Central Nervous System Tumors, Metastatic Cancer
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00547131
- Testing
- temozolomide, laboratory biomarker analysis, liquid chromatography
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Brain Metastases from Non-small Cell Lung Cancer
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
This is a research study to find out if the new anti-cancer drug Durvalumab combined with radiation therapy to the brain will work in treating brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT04889066
- Testing
- Stereotactic Radiation Therapy, Durvalumab
- Sponsor
- University of Texas Southwestern Medical Center
Central Nervous System Tumor
Medical and Surgical Management of Patients With Brain Metastases
The integrated cancer research site (SIRIC) of Montpellier proposes to develop a prospective and regional Clinical Database Project and regional biological collection (blood and tumor samples), which is an expanding data…
- Trial name
- CEREMET-LR (NCT03981016)
- Testing
- Biological collection
- Where
- 12 sites in France
- Volunteers
- 105 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Leptomeningeal Metastases, Leptomeningeal Disease
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.
- Trial name
- NCT03719768
- Testing
- Avelumab, Whole Brain Radiotherapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
TNBC, Triple Negative Breast Cancer, Brain Metastasases
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
This is an open-label, prospective, two-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with…
- Trial name
- ABC-R (NCT07638852)
- Testing
- Radiation Therapy, Adebelimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Advanced Solid Tumors
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer…
- Trial name
- EIK1004-001 (NCT06907043)
- Testing
- EIK1004-001 (IMP1707-001)
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 130 people
- Sponsor
- Eikon Therapeutics
Malignant Primary Brain Tumors, Brain Metastases, Adult
Safety Study of Pritumumab in Brain Cancer
Pritumumab is a human IgG1 kappa antibody that binds to a malignant tumor associated antigen, ecto domain-vimentin (EDV) which is expressed in a variety of tumor cells.
- Trial name
- NCT04396717
- Testing
- Pritumumab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Nascent Biotech
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials
PET-CT
Performance of Amino Acid Positons Emission Tomography in Brain Metastases
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications
- Trial name
- DYNAMET (NCT07676448)
- Testing
- PET exam analysis
- Volunteers
- 80 people
- Sponsor
- Central Hospital, Nancy, France
Small Cell Lung Cancer, Brain Metastases, Adult
Tarlatamab for SCLC Brain Metastases
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
- Trial name
- T-BRAIN (NCT07402343)
- Testing
- Tarlatamab
- Where
- 4 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- Maastricht University Medical Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04348747
- Testing
- Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Brain Metastases
Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases
The purpose of this study is to evaluate the safety of BBB disruption using the ExAblate 4000-system Type 2 in patients with Her-2 positive breast cancer metastases in the brain.
- Trial name
- BBBD (NCT03714243)
- Testing
- ExAblate BBBD
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- InSightec
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site…
- Conditions
- Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
- Trial name
- NCT02360215
- Testing
- Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
- Where
- 220 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- NRG Oncology
Brain Metastases
Stereotactic Radiosurgery With Sunitinib for Brain Metastases
The purpose of this study is to determine the maximum dose of sunitinib that can be tolerated when treatment is combined with radiotherapy.
- Trial name
- NCT00981890
- Testing
- Sunitinib
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.